Anavex Life Sciences Corp.
AVXL· Nasdaq
AVXLAnavex Life Sciences Corp.
Filed Aug 6, 2024 · 10-Q · 37 days after period end · 0001731122-24-001207
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Net Income | -$12.21M | -$11.28M | -$12.37M | -$10.18M |
| EPS Diluted | -$0.14 | -$0.14 | — | -$0.14 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Anavex Life Sciences Corp. · CIK 1314052 · Engraved from SEC EDGAR
ended Jun 30, 2024 · filed Aug 6, 2024 · 37 d after period end
